Aethlon Medical Q1 operating expenses fall on lower professional fees

Aethlon Medical

13/08/2026 22:36

Overview
US clinical-stage therapeutic firm's fiscal Q1 operating expenses fell 12% yr/yr, reducing operating loss
Company ended Q1 with $4.9 mln cash, raised $4.0 mln post-quarter via stock offering
First participant dosed in final cohort of Phase 1 oncology study for Hemopurifier

Outlook
Company expects cash resources to fund operations for at least the next 12 months

Result Drivers
LOWER OPERATING EXPENSES - Co said Q1 operating expenses fell 12% yr/yr due to lower professional fees and reduced general and administrative and preclinical research costs
CLINICAL PROGRAM PROGRESS - Co dosed first participant in final cohort of Phase 1 oncology study and reported preliminary biomarker signals supporting continued evaluation of Hemopurifier

Company press release: ID:nPn5Y3w9ta

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Loss Per Share
 
$4.02
 

Analyst Coverage
The current average analyst rating on the shares is "hold" and the breakdown of recommendations is no "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the advanced medical equipment & technology peer group is "buy."
Wall Street's median 12-month price target for Aethlon Medical Inc is $10.00, about 228.9% above its August 12 closing price of $3.04

Reuters Recommended Reads
Aug 12 - Oncology device maker RenovoRx's Q2 revenue surges, raises FY outlook
Aug 11 - Oncology firm Immunome's Q2 net loss widens as R&D costs rise
Aug 13 - Aktis Oncology Q2 net loss widens on higher R&D, administrative costs

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)